日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry

elexacaftor/tezacaftor/ivacaftor 对 ≥6 岁囊性纤维化患者大小气道的长期影响:来自德国囊性纤维化注册研究的 24 个月真实世界证据

Dillenhöfer, Stefanie; Schütz, Katharina; Burkhart, Manuel; Ellemunter, Helmut; Kappler, Matthias; Sieber, Sarah; Naehrlich, Lutz; Brinkmann, Folke; Sutharsan, Sivagurunathan

Detection of cytokines in nasal lavage samples of patients with cystic fibrosis: comparison of two different cytokine detection assays

囊性纤维化患者鼻腔冲洗液样本中细胞因子的检测:两种不同细胞因子检测方法的比较

Fuchs, Teresa; Zlamy, Manuela; Zöggeler, Thomas; Appelt, Dorothea; Niedermayr, Katharina; Siedl, Anja; Gasser, Verena; Eder, Johannes; Ellemunter, Helmut

Bridging of host-microbiota tryptophan partitioning by the serotonin pathway in fungal pneumonia

在真菌性肺炎中,血清素途径介导宿主-微生物群色氨酸分配

Giorgia Renga, Fiorella D'Onofrio, Marilena Pariano, Roberta Galarini, Carolina Barola, Claudia Stincardini, Marina M Bellet, Helmut Ellemunter, Cornelia Lass-Flörl, Claudio Costantini, Valerio Napolioni, Allison K Ehrlich, Cinzia Antognelli, Massimo Fini, Enrico Garaci, Emilia Nunzi #, Luigina Roma

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry

elexacaftor/tezacaftor/ivacaftor 对囊性纤维化患者肺功能、营养状况、肺部急性加重频率和汗液氯化物的影响:来自德国囊性纤维化登记处的真实世界证据

Sutharsan, Sivagurunathan; Dillenhoefer, Stefanie; Welsner, Matthias; Stehling, Florian; Brinkmann, Folke; Burkhart, Manuel; Ellemunter, Helmut; Dittrich, Anna-Maria; Smaczny, Christina; Eickmeier, Olaf; Kappler, Matthias; Schwarz, Carsten; Sieber, Sarah; Naehrig, Susanne; Naehrlich, Lutz

Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis-a real world study

一项真实世界研究显示,在接受 elexacaftor/tezacaftor/ivacaftor 治疗 2 至 16 周后,囊性纤维化患者的肺清除指数早期且持续改善。

Appelt, Dorothea; Steinkamp, Gratiana; Sieber, Sarah; Ellemunter, Helmut

Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

针对囊性纤维化潜在蛋白质缺陷的个性化药物治疗:是否需要监测治疗反应?

Niedermayr, Katharina; Gasser, Verena; Rueckes-Nilges, Claudia; Appelt, Dorothea; Eder, Johannes; Fuchs, Teresa; Naehrlich, Lutz; Ellemunter, Helmut

Malignancies in patients with cystic fibrosis: a case series

囊性纤维化患者的恶性肿瘤:病例系列

Appelt, Dorothea; Fuchs, Teresa; Steinkamp, Gratiana; Ellemunter, Helmut

REAL-world clinical effectiveness of ivacaftor therapy in the first 24 months in two infants with cystic fibrosis and different gating mutations-A case report

伊伐卡托治疗在两名患有囊性纤维化且携带不同门控突变的婴儿中,于出生后24个月内的真实世界临床疗效——病例报告

Fuchs, Teresa; Appelt, Dorothea; Niedermayr, Katharina; Ellemunter, Helmut

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid

Ivacaftor 可减少 G551D 突变囊性纤维化患者上呼吸道内壁液中的炎症介质:连续非侵入性家庭上呼吸道内壁液收集

Jochen G Mainz, Christin Arnold, Kara Wittstock, Uta-Christina Hipler, Thomas Lehmann, Carlos Zagoya, Franziska Duckstein, Helmut Ellemunter, Julia Hentschel

Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters

奥地利新生儿囊性纤维化筛查采用PAP及其与IRT浓度乘积作为二级参数

Zeyda, Maximilian; Schanzer, Andrea; Basek, Pavel; Bauer, Vera; Eber, Ernst; Ellemunter, Helmut; Kallinger, Margit; Riedler, Josef; Thir, Christina; Wadlegger, Franz; Zacharasiewicz, Angela; Renner, Sabine